124 related articles for article (PubMed ID: 35780816)
1. Minimum Volume Standards for Surgical Care of Early-Stage Lung Cancer: A Cost-Effectiveness Analysis.
Subramanian MP; Yang Z; Chang SH; Willis D; Zhang J; Semenkovich TR; Heiden BT; Kozower BD; Kreisel D; Meyers BF; Patterson GA; Nava RG; Puri V
Ann Thorac Surg; 2022 Dec; 114(6):2001-2007. PubMed ID: 35780816
[TBL] [Abstract][Full Text] [Related]
2. The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.
Samson P; Patel A; Robinson CG; Morgensztern D; Chang SH; Colditz GA; Waqar S; Crabtree TD; Krupnick AS; Kreisel D; Patterson GA; Meyers BF; Puri V
Ann Thorac Surg; 2015 Dec; 100(6):2026-32; discussion 2032. PubMed ID: 26319488
[TBL] [Abstract][Full Text] [Related]
3. Association of Discretionary Hospital Volume Standards for High-risk Cancer Surgery With Patient Outcomes and Access, 2005-2016.
Sheetz KH; Chhabra KR; Smith ME; Dimick JB; Nathan H
JAMA Surg; 2019 Nov; 154(11):1005-1012. PubMed ID: 31411663
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Robotic-assisted Lobectomy for Non-Small Cell Lung Cancer.
Heiden BT; Mitchell JD; Rome E; Puri V; Meyers BF; Chang SH; Kozower BD
Ann Thorac Surg; 2022 Jul; 114(1):265-272. PubMed ID: 34389311
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.
Witlox WJA; Ramaekers BLT; Lacas B; Le Pechoux C; Sun A; Wang SY; Hu C; Redman M; van der Noort V; Li N; Guckenberger M; van Tinteren H; Hendriks LEL; Groen HJM; Joore MA; De Ruysscher DKM
Radiother Oncol; 2022 May; 170():95-101. PubMed ID: 35259416
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
Smith BD; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Shirvani SM
J Geriatr Oncol; 2015 Jul; 6(4):324-31. PubMed ID: 26094172
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
[TBL] [Abstract][Full Text] [Related]
12. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Han J; Tian K; Yang J; Gong Y
Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
17. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
Chen D; Kang P; Tao S; Li Q; Wang R; Tan Q
Lung Cancer; 2021 Mar; 153():99-107. PubMed ID: 33482409
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.
Li W; Wan L
Front Public Health; 2022; 10():1015702. PubMed ID: 36408023
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
